Prokop Mathias, Schaefer-Prokop Cornelia, Jacobs Colin, Snoeckx Annemiek, Biederer Jürgen, Frauenfelder Thomas, Gleeson Fergus, Kauczor Hans-Ulrich, Parkar Anagha P, Vliegenthart Rozemarijn, Revel Marie-Pierre, Silva Mario, Prosch Helmut
Department of Medical Imaging, Radboud University Center, Nijmegen, The Netherlands.
Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands.
Eur Radiol. 2025 Jul 1. doi: 10.1007/s00330-025-11647-5.
The European Society of Thoracic Imaging (ESTI) nodule management recommendation for lung cancer screening with low-dose CT builds on existing nodule management guidelines but puts a stronger focus on lesion aggressiveness and measurement error. Key objectives included finding a compromise between the overall number of follow-up examinations, avoiding a major stage shift, and reducing the risk for overtreatment. Nodule management categories at baseline are chosen depending on the size of a solid nodule or the solid component of a subsolid or cystic nodule, with suspicious morphology upgrading risk to the next higher category. Higher risk categories mandate shorter follow-up times or diagnostic workup. Volume is the preferred size measure, with diameter measurements as a fallback if segmentation for volumetry is inaccurate at visual control. Nodule aggressiveness at follow-up is estimated from growth rate, calculated as volume doubling time (VDT), or yearly diameter change. Calculation of growth rate, however, is strongly affected by measurement variability, with large error margins for short follow-up and slower growing lesions. Growth thresholds were therefore set so that rapidly growing lesions can be identified while still small, while unnecessary workups for benign or slow-growing lesions could be kept low. New lesions that are retrospectively visible on earlier scans are managed according to their growth rate. New nodules not visible on earlier scans are followed after 3 months if they have a volume of ≥ 30 mm. KEY POINTS: Question This work strives to reduce follow-up examinations while preventing major stage shift and overtreatment. It provides nodule management based on estimated nodule aggressiveness. Findings Calculation of the growth rate of pulmonary nodules is strongly affected by measurement variability, with large error margins for short follow-up and slower growing lesions. Clinical relevance Growth thresholds that trigger management are adjusted to the follow-up time so that rapidly growing lesions can be identified while still being small while unnecessary workups for benign or slow-growing lesions can be reduced.
欧洲胸科影像学会(ESTI)关于低剂量CT肺癌筛查的结节管理建议以现有的结节管理指南为基础,但更加强调病变的侵袭性和测量误差。主要目标包括在随访检查的总数之间找到平衡,避免重大分期改变,并降低过度治疗的风险。基线时的结节管理类别根据实性结节的大小或亚实性或囊性结节的实性成分来选择,形态可疑则将风险升级到下一个更高类别。更高风险类别要求更短的随访时间或诊断性检查。体积是首选的大小测量指标,如果在视觉控制下体积测量的分割不准确,则以直径测量作为备用方法。随访时结节的侵袭性通过生长率来估计,生长率以体积倍增时间(VDT)或年直径变化来计算。然而,生长率的计算受到测量变异性的强烈影响,对于短期随访和生长较慢的病变,误差幅度较大。因此设定了生长阈值,以便在病变仍较小时就能识别出快速生长的病变,同时尽量减少对良性或生长缓慢病变的不必要检查。在早期扫描中可追溯到的新病变根据其生长率进行管理。如果新结节体积≥30 mm,则在3个月后进行随访。关键点:问题 这项工作致力于减少随访检查,同时防止重大分期改变和过度治疗。它基于估计的结节侵袭性提供结节管理。发现 肺结节生长率的计算受到测量变异性的强烈影响,对于短期随访和生长较慢的病变,误差幅度较大。临床意义 触发管理的生长阈值根据随访时间进行调整,以便在病变仍较小时就能识别出快速生长的病变,同时减少对良性或生长缓慢病变的不必要检查。